http://www.philly.com/mld/philly/14687073.htm

"And the Inquirer reports that "NAMI, did not disclose that Lilly 
marketing manager
Gerald Radke briefly ran its entire operation. Radke began in 1999 as a
Lilly-paid "management consultant," then left Lilly and served as NAMI's
paid "interim executive director" until mid-2001. The group acknowledged
this only after being shown Radke's resume listing the job.

"Lilly donated at least $3 million to NAMI. For its part, NAMI promotes the
increased use of psychotropic drugs, lobbies against any cost-saving
restrictions on number of psychotropic drugs prescribed for one patient
under Medicaid, and even lobbies for laws allowing mental patients to be
forced to take antipsychotic drugs. The drugs most often prescribed for
involuntary patients-Janssen's Risperdal (risperidone) and Lilly's Zyprexa
(olanzapine)-cause debilitating, indeed, lethal effects. . NAMI's failure to
inform its constituents about the danger these drugs pose for patients, and
its continued aggressive promotion of these drugs despite the evidence, may
be viewed as confirmation that NAMI is an extension of Lilly's marketing
department."

Vera Sharav


"People Who experience mood swings, fear, voices and visions"